An evaluation of CYP3A4 drug interactions with HMG-CoA reductase inhibitors

Formulary

Volumn 35, Issue 4, 2000, Pages 343-352

  White, C Michael ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ATORVASTATIN; AZITHROMYCIN; BAYCHOL; CERIVASTATIN; CYCLOSPORIN; CYTOCHROME P450 3A; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; FLUINDOSTATIN; FLUVOXAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; METRONIDAZOLE; MEVINOLIN; MIBEFRADIL; MICONAZOLE; NELFINAVIR; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; SIMVASTATIN; TROLEANDOMYCIN; UNINDEXED DRUG; VERAPAMIL; ZILEUTON;

AREA UNDER THE CURVE; CLINICAL TRIAL; DECISION MAKING; DISEASE EXACERBATION; DRUG MECHANISM; FOOD DRUG INTERACTION; GRAPE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; META ANALYSIS; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT;

EID: 0034007598     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. White CM. Pharmacological effects of HMG-CoA reductase inhibitors other than lipoprotein modulation. J Clin Pharmacol 1999;39:111-8.
2. Expert NCEP Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1993;269:3015-23.
3. Schassmann D, Bulligham R, Gasser R, et al. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 1998;351:1929-30.
4. Michalets EL. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84-112.
5. Cupp MJ, Tracy TS. Role of the cytochrome P450 3A subfamily in drug inter-actions. US Pharmacist 1997;22:HS9-21.
6. Desager JP, Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet 1996;31:348-71.
7. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998;64:58-65.
8. Muck W. Rational assessment of the inter-action profile of cerivastatin supports its low propensity for drug interactions. Drugs 1998;56(Suppl 1):15-23.
9. Knochel JP. Mechanisms of rhabdomyolysis. Curr Opin Rheumatol 1993;5/6:725-31.
10. Girolami UD, Anthony DC, Frosch MP. Chapter 28, Peripheral nerve and skeletal muscle. In: Cotran RS, Kumar V, Robbins SL, eds, Robbins Pathologic Basis of Disease, 5th ed. Philadelphia, PA: WB Saunders, Co;1994:1273-94.
11. Berkow R, Fletcher AJ, eds. The Merck Manual of Diagnosis and Therapy, 16th ed. Rathway, NJ: Merck & Co, Inc;1992.
12. Horn M. Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals. Arch Dermatol 1996;132:1254.
13. Lees RS, Lees AM. Rhabdomyolysis from the Coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995;333:664.
14. Ayanian JZ, Fuchs CS, Stone RM. Lovastatin and rhabdomyolysis. Ann Intern Med 1988;109:682.
15. Spach DH, Bauwens JE, Clark CD, et al. Rhabdomyolysis associated with lovastatin and erythromycin use. Western J Med 1991;154:213-5.
16. Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use - Report of two cases in cardiac transplant recipients. JAMA 1988;260:239-41.
17. Wong PW, Dillard TA, Kroenke K. Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy. Southern Med J 1998;91:202-5.
18. Grunden JW, Fischer KA. Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Ann Pharmacother 1997;31:859-63.
19. Jacobson RH, Wang P, Glueck CJ. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. JAMA 1997;277:296-7.
20. Norman DJ, Illingworth DR, Munson J, et al. Myolysis and acute renal failure in a heart transplant recipient receiving lovastatin. N Engl J Med 1988;318:46-7.
21. Alejandro DS, Petersen J. Myoglobinuric acute renal failure in a cardiac transplant patient taking lovastatin and cyclosporine. J Am Soc Nephrol 1994;5:153-60.
22. East C, Grundy SM, Jones PH. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988;318:47-8.
23. Kogan AD, Orenstein S. Lovastatin-induced acute rhabdomyolysis. Postgrad Med J 1990;66:294-6.
24. Ballantyne CM, Radovancevic B, Farmer JA, et al. Hyperlipidemia after heart transplantation: Report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol 1992;19:1315-21.
25. Ahmad S. Diltiazem myopathy. Am Heart J 1993;126:1494-5.
26. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998;64:58-65.
27. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60:54-61.
28. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-41.
29. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998;64:177-82.
30. Mück W, Ochmann K, Rhode G, et al. Influence of erythromycin pre-and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol 1998;53:469-73.
31. Azie N, Brater C, Becker PA, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998; 64:369-77.
32. Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporinee-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997;62:311-21.
33. Muck W, Mai I, Fritsche L, et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 1999;65:251-61.
34. Arnadottir M, Eriksson LO, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993;65:410-3.
35. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998;63:397-402.
36. Lija JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998; 64:477-83.
37. Anonymous. AHFS first FAX drug overview of amprenavir. AJHP 1999;56: 1365-6. F